Literature DB >> 29650788

Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma.

Hong Xu1, Yueming Chen2, Xueyan Dong1, Xianjun Wang1.   

Abstract

Background: Increasing studies suggest that long noncoding RNAs (lncRNAs) are involved in carcinogenesis of human cancers and might be used as diagnostic biomarkers for cancers.
Methods: A total of 301 participants were recruited in the first part of the study, including a hepatocellular carcinoma (HCC) group (n = 60), liver cirrhosis (LC) group (n = 85), chronic hepatitis B (CHB) group (n = 96), and healthy subjects (n = 60). In the second part, we collected 55 HCC patients, 60 CHB patients, and 60 healthy subjects as an independent cohort to validate the ability of the experiential lncRNAs for identifying HCC from CHB. A commercial kit was used to isolate serum exosomes and total RNA. The relative levels of lnRNAs and GAPDH mRNA were measured with TaqMan PCR.
Results: The results showed that the levels of ENSG00000258332.1 and LINC00635 in the HCC group were significantly higher than those in the other groups (all P < 0.05). A high ENSG00000258332.1 level in HCC was associated with portal vein tumor emboli, lymph node metastasis, TNM stage, and overall survival (OS; all P < 0.05), and a high LINC00635 level was related to lymph node metastasis, TNM stage, and OS (all P < 0.05). ENSG00000258332.1 discriminated HCC from CHB, gaining an area under the ROC curve (AUC) of 0.719 (cutoff value of 1.345); LINC00635 gained an AUC of 0.750 (cutoff value of 1.690). Furthermore, the AUC for the combination of the 2 lncRNAs and serum AFP (cutoff value of 20 μg/L) was 0.894. The abilities of the 2 lncRNAs for identifying HCC from CHB were validated by an independent cohort.Conclusions: The results suggested that the combination of serum exosomal ENSG00000258332.1, LINC00635, and AFP may be a valuable assay in diagnosis and prognosis of HCC.Impact: Our data will shed light on exosomal lncRNAs as biomarkers for HCC. Cancer Epidemiol Biomarkers Prev; 27(6); 710-6. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29650788     DOI: 10.1158/1055-9965.EPI-17-0770

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  49 in total

Review 1.  The functional role of exosome in hepatocellular carcinoma.

Authors:  Hongyu Liu; Baoguo Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

Review 2.  Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma.

Authors:  Changbiao Li; Xiao Xu
Journal:  Cell Mol Life Sci       Date:  2019-07-12       Impact factor: 9.261

Review 3.  Clinical implications of exosome-derived noncoding RNAs in liver.

Authors:  Zhe Wen Zhou; Wei Zheng; Zheng Xiang; Cun Si Ye; Qiao Qiao Yin; Shou Hao Wang; Cheng An Xu; Wen Hao Wu; Tian Chen Hui; Qing Qing Wu; Ling Yun Zhao; Hong Ying Pan; Ke Yang Xu
Journal:  Lab Invest       Date:  2022-01-10       Impact factor: 5.662

Review 4.  Exosomal non-coding RNAs: Emerging roles in bilateral communication between cancer cells and macrophages.

Authors:  Wenhao Li; Xiaolong Wang; Chen Li; Tong Chen; Qifeng Yang
Journal:  Mol Ther       Date:  2021-12-02       Impact factor: 11.454

Review 5.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.

Authors:  Vincent L Chen; Dabo Xu; Max S Wicha; Anna S Lok; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-11       Impact factor: 11.382

Review 6.  The functional roles of exosomal long non-coding RNAs in cancer.

Authors:  Man Wang; Li Zhou; Fei Yu; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cell Mol Life Sci       Date:  2019-01-25       Impact factor: 9.261

Review 7.  Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Authors:  Filippo Pelizzaro; Romilda Cardin; Barbara Penzo; Elisa Pinto; Alessandro Vitale; Umberto Cillo; Francesco Paolo Russo; Fabio Farinati
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

Review 8.  Biomarkers for hepatocellular carcinoma based on body fluids and feces.

Authors:  Ming-Cheng Guan; Wei Ouyang; Ming-Da Wang; Lei Liang; Na Li; Ting-Ting Fu; Feng Shen; Wan-Yee Lau; Qiu-Ran Xu; Dong-Sheng Huang; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

9.  Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma.

Authors:  Meng-Yuan Yang; Fan Wu; Feng Fang; Hao Yang; Jing-Fan Zhang; Guo-Dong Chen; Lian-Yue Yang
Journal:  BMC Cancer       Date:  2021-07-03       Impact factor: 4.430

Review 10.  Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment.

Authors:  Mengtao Xing; Xinzhi Wang; Robert A Kiken; Ling He; Jian-Ying Zhang
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.